Major U.S. indices ended mixed on Monday, with the Dow Jones Industrial Average slipping 0.07% to 51,966.03.
Gainers Silence Therapeutics (NASDAQ:SLN) stock increased by 125.6% to $19.59 during Monday's regular session. The market value of their outstanding shares is at $581.1 million. SCWorx (NASDAQ:WORX) stock
Silence Therapeutics (SLN) leaps 126% on a $1.3B cash acquisition by Merck KGaA at $20 per ADS. Deal expected to close Q1 2027.
U.S. stocks mixed as Dow fell ~100 points; Silence Therapeutics surged 125.7% on Merck KGaA buyout, while biotech and tech shares gained.
Merck said it is offering $20 in cash for each American depositary share for Nasdaq-listed Silence Therapeutics, more than double the target’s closing price as of Friday.
Silence Therapeutics stock surges as Merck KGaA agrees to acquire the RNA drugmaker for over $1 billion.
The heavy selling pressure might have exhausted for Silence Therapeutics (SLN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Silence Therapeutics (SLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
This is the newest page. Registered accounts read further back.